===
EQS-News: PharmaSGP Holding SE / Key word(s): Preliminary Results/Forecast
PharmaSGP exceeds the EUR 100 million revenues mark in 2023 and plans further profitable growth in 2024
2024-04-16 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
PharmaSGP exceeds the EUR 100 million revenues mark in 2023 and plans further profitable growth in 2024
Gräfelfing, April 16, 2024 - German OTC pharmaceutical company PharmaSGP Holding SE continued the successful
development of previous years in the 2023 financial year and exceeded the EUR 100 million revenues mark for the first
time in the company's history at EUR 101.1 million based on preliminary, unaudited figures. The increase in revenues of
17.8% compared to the prior-year period (EUR 85.8 million) is based on the strong organic growth achieved by PharmaSGP
through the consequent execution of its well-proven platform strategy. Adjusted earnings before interest, taxes,
depreciation and amortization (adjusted EBITDA) amounted to EUR 34.1 million in the 2023 financial year, an increase of
20.8% compared to the previous year (EUR 28.2 million). As a result, the adjusted EBITDA margin rose to 33.7% (previous
year: 32.9%). Both revenues and adjusted EBITDA are slightly above the 2023 forecast.
CEO Natalie Weigand comments: "With great satisfaction we look back on a successful financial year 2023, in which we
achieved a strong performance in terms of both revenues and profitability. The fact that we achieved our growth
exclusively organically demonstrates the sustainable strength of our platform strategy and the efficiency of our
marketing activities."
CFO Michael Rudolf adds: "We reached a milestone last year by exceeding the EUR 100 million revenues mark for the first
time. The fact that we slightly exceeded our forecast in terms of revenues and adjusted EBITDA in an overall
challenging market environment impressively underlines the resilience of our growth strategy. This will also enable us
to achieve further growth in the future and to optimally exploit the potential of our business model."
For the current 2024 financial year, the Management Board of PharmaSGP expects the success story to continue with
revenues in a range between EUR 107.0 million and EUR 112.0 million. The Management Board is also forecasting a further
increase in adjusted EBITDA with earnings of between EUR 35.0 million and EUR 38.0 million. This corresponds to an adjusted
EBITDA margin of 32.7% to 33.9%.
PharmaSGP will publish its full annual report for 2023 on 29 April, 2024.

OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FIGURES

Consolidated figures (in EUR million)          2023  2022      ? 
Revenues                                    101.1  85.8 +17.8% 
Adjusted EBITDA                              34.1  28.2 +20.8% 
Unadjusted EBITDA                            34.0  26.9 +26.3% 
Adjusted EBITDA margin                      33.7% 32.9% 
Unadjusted EBITDA margin                    33.6% 31.4% 

Revenues by region (in EUR million)            2023  2022      ? 
Germany                                      73.4  61.3 +19.6% 
Italy                                        13.6  10.5 +28.8% 
Austria                                      10.5   9.8  +7.8% 
Other European countries                      3.7   4.2 -13.0% 

Revenues share by region                     2023  2022 
Germany                                     72.6% 71.5% 
Italy                                       13.4% 12.3% 
Austria                                     10.4% 11.4% 
Other European countries                     3.6%  4.8% 

Revenues by product category (in EUR million)  2023  2022      ? 
Health Brands                                97.5  82.5 +18.2% 
Beauty Brands                                 3.5   3.3  +6.0% 

===
CONTACT

cometis AG Claudius Krause Phone: +49-611-20585528 Email: ir@pharmasgp.com

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran ^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2023, PharmaSGP generated revenues of EUR 101.1 million at an adjusted EBITDA margin of 33.7% based on preliminary, unaudited figures.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.

-----------------------------------------------------------------------------------------------------------------------

2024-04-16 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

-----------------------------------------------------------------------------------------------------------------------

===

Language:     English 
Company:      PharmaSGP Holding SE 

Lochhamer Schlag 1
82166 Gräfelfing
Germany

E-mail:       ir@pharmasgp.com 
Internet:     https://pharmasgp.com 
ISIN:         DE000A2P4LJ5 
WKN:          A2P4LJ 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Munich, Tradegate Exchange
EQS News ID: 1880509

End of News EQS News Service
===
1880509 2024-04-16 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1880509&application_name=news

END) Dow Jones Newswires

April 16, 2024 01:30 ET (05:30 GMT)